Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Intravenous Ulimorelin (LP101) in Patients With Enteral Feeding Intolerance (EFI)

NCT02784392 is registered in ClinicalTrials.gov with Lyric Pharmaceuticals as lead sponsor.

NCT NCT02784392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02784392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Intravenous Ulimorelin (LP101) in Patients With Enteral Feeding Intolerance (EFI)
Lead sponsor
Lyric Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2016
Completion date
March 31, 2018
Enrollment
120 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

enteral feeding intolerance (efi)